DAFNA Capital Management LLC Sells 59,319 Shares of KalVista Pharmaceuticals, Inc. $KALV

DAFNA Capital Management LLC lessened its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 7.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 752,359 shares of the specialty pharmaceutical company’s stock after selling 59,319 shares during the quarter. KalVista Pharmaceuticals comprises about 2.5% of DAFNA Capital Management LLC’s investment portfolio, making the stock its 13th largest position. DAFNA Capital Management LLC owned approximately 1.51% of KalVista Pharmaceuticals worth $8,682,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Earned Wealth Advisors LLC acquired a new stake in shares of KalVista Pharmaceuticals during the 1st quarter worth approximately $44,000. GAMMA Investing LLC lifted its stake in shares of KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock valued at $51,000 after purchasing an additional 3,767 shares during the period. CWM LLC boosted its position in shares of KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 4,549 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth $44,000. Finally, Tower Research Capital LLC TRC increased its holdings in KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 5,502 shares during the last quarter.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,336 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $13.42, for a total value of $31,349.12. Following the sale, the insider owned 122,505 shares in the company, valued at $1,644,017.10. This represents a 1.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Benjamin L. Palleiko sold 10,940 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $144,626.80. Following the sale, the chief executive officer owned 386,858 shares in the company, valued at $5,114,262.76. This trade represents a 2.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,710 shares of company stock valued at $880,764. Corporate insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Trading Down 0.4%

KALV opened at $13.46 on Friday. The company’s 50 day moving average is $13.50 and its 200-day moving average is $12.46. The company has a market cap of $677.58 million, a P/E ratio of -3.65 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $16.32.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period last year, the business posted ($1.07) EPS. On average, equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Leerink Partners increased their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, July 7th. JMP Securities upped their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a “market outperform” rating in a report on Tuesday, July 8th. Finally, HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $26.29.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).